DURBAN, South Africa — While the world has made progress reducing the number of people who die from AIDS every year by expanding access to life-saving drug treatments, many countries are increasingly failing to prevent the spread of HIV. That’s the disturbing gist of a new report released here at the 21st International AIDS Conference
While the guidelines are clear about the need to treat tuberculosis in the setting HIV infection, the reality is that many patients with HIV/TB co-infection Read More
No abstract available
Huffington Post: The Shifting Diplomacy around Migration, HIV/AIDS, and Tuberculosis in Central Asia Michel Kazatchkine, U.N. special envoy for HIV/AIDS in Eastern Europe and Central Asia “…To reverse the rising HIV and [multidrug-resistant TB (MDR-TB)] epidemics, the [Eastern Europe and Central Asia] region will need to move forward on a number of fronts: Firstly, there…More
Categories: U.S. Policy and FundingA few days after the White House released an outline of budget priorities, that included a nearly 20 percent cut to medical research funding, and elimination of the global health study supporting Fogarty International Center, four physician scientists who have dedicated their careers to fighting HIV and tuberculosis came to Capitol Hill to talk about […](Read more…)
NBC News: Amid Dramatic Cuts, HIV/AIDS Funding Spared in New Trump Budget “One surprise winner in the proposed Trump administration budget will be HIV/AIDS funding, despite a nearly 18 percent cut to the Department of Health and Human Services. … The budget promises to ‘provide sufficient resources to maintain current commitments and all current patient…More
The Lancet: Venezuela’s economic crisis hampers HIV/AIDS treatment “Amid an ongoing economic crisis, Venezuela is experiencing shortages of several HIV drugs, including those to prevent mother-to-child transmission of the virus…” (Daniels, 3/18).
Financial Times: HIV/AIDS drugs for developing world face threat of disruption Brian Elliott, chief executive of Procela Consultants “…Fifteen generic manufacturers supply more than 95 percent of [antiretroviral drugs (ARVs)] to [low- to middle-income countries (LMICs)], of which four supply the bulk — 83 percent. … Reliance on so few suppliers for continuing treatment for…More
Mic: Co-chairs of Congressional HIV/AIDS Caucus urge Trump to take action to end epidemic “Throughout his campaign and tenure as president thus far, Donald Trump has remained relatively mum on the issue of HIV/AIDS. But in a letter sent to the president on Tuesday, the co-chairs of the Congressional HIV/AIDS Caucus urged Trump to continue…More
Categories: U.S. Policy and FundingFrom the handful of people — 50,000 — across Africa with access to life-saving treatment for HIV in 2003, to more than 18 million today, the chronology of U.S. leadership against the pandemic that was filling graveyards, orphaning infants, and decimating the continent’s most productive population, when President George W. Bush signed the legislation creating […](Read more…)
Categories: What we’re readingOpen letter to the WHO to put #TBontheList – “WHO: When you make a mistake, fix it,” former CDC head Dr. Tom Frieden tweeted last week, after TB research and response advocates reacted to the World Health Organization’s omission of tuberculosis from its a list of “priority pathogens” demanding urgent research and development efforts. Now […](Read more…)
The Hill: Women and Girls HIV/AIDS Awareness Day — let’s empower women globally Kelsey Louie, chief executive officer at Gay Men’s Health Crisis (GMHC) “…On National Women and Girls HIV/AIDS Awareness Day, it is imperative that we recognize the threat of HIV facing women of all ages, encourage steps towards ending the epidemic among women,…More
U.S. Department of State’s “DipNote”: International Women’s Day 2017: A Time for Action Deborah Birx, ambassador-at-large, coordinator of U.S. government activities to combat HIV/AIDS, and U.S. special representative for global health diplomacy, highlights International Women’s Day, and discusses girls’ vulnerability to HIV and PEPFAR’s efforts to address HIV, especially among this population. Birx writes, “PEPFAR’s…More
Background: Prompt entry into HIV care is often hindered by personal and structural barriers.
Introduction: Approximately 80% of patients with hemophilia who received nonheated coagulation factor concentrates in the early 1980s were infected with hepatitis C virus (HCV), and approximately 40% of them were infected with HIV.
Over the past two decades, the role of good governance in aid effectiveness has been a topic of debate. Both donor and recipient countries have questioned why investments of official development assistance (ODA) over many years have not resulted in stronger economic and health outcomes. This blog post focuses on health aid (in particular HIV/AIDS aid) and the impact control of corruption and democratic accountability may have on improving health outcomes. More than 95% of HIV infections are in developing countries. As a result, global communities have invested billions of dollars in the fight against HIV/AIDS using funding from ODA and other substantial donors.
Categories: CROI 2017In injections or implants, technology that eliminates daily pill taking, and with it “pill fatigue,” stigma, and other barriers to adherence, has already proven its value, and is on the horizon for HIV SEATTLE – Surveys indicate that the majority of people living with HIV would be happier with a monthly injection than a daily pill. At […](Read more…)